Form 4: STERIS plc CEO Daniel Carestio Receives Significant Equity Grant, Aligning Interests with Shareholders

STERIS plc's President and CEO, Daniel A. Carestio, has been granted 17,811 ordinary shares and 63,328 employee stock options, reinforcing his stake in the company's future performance.

Summary

• Daniel A. Carestio, President and CEO, and a Director of STERIS plc (STE), acquired 17,811 ordinary shares on June 3, 2025, as part of an equity grant.
• These ordinary shares were acquired at a price of $0, indicating they were likely a compensation award.
• Following this transaction, Mr. Carestio beneficially owns 70,932 ordinary shares, of which 37,626 are restricted and subject to various vesting schedules through June 5, 2028.
• Additionally, Mr. Carestio was granted 63,328 employee stock options on June 3, 2025, with an exercise price of $267.66 per share.
• These stock options will become exercisable in four equal tranches of 15,832 shares each, annually from June 3, 2026, through June 4, 2029, and expire on June 3, 2035.

Sentiment

Score: 7

Explanation: The document reports a standard executive equity grant, which is generally positive as it aligns management's interests with shareholders. There are no negative implications or unexpected events reported.

Positives

• The grant of ordinary shares and stock options to the President and CEO, Daniel A. Carestio, aligns his personal financial interests directly with the long-term performance and shareholder value of STERIS plc.
• Equity compensation is a standard practice that incentivizes executive retention and performance, fostering a commitment to the company's strategic goals.

Future Outlook

The vesting schedules for the restricted ordinary shares and employee stock options indicate a future increase in Daniel A. Carestio's unrestricted ownership and exercisable options over the next several years, contingent on continued employment and performance.

Industry Context

This Form 4 filing represents a routine disclosure of executive equity compensation, a common practice across industries to align management incentives with shareholder interests and retain key talent.

Stakeholder Impact

• Shareholders: The equity grants align the interests of the President and CEO with those of the shareholders, potentially leading to more focused efforts on long-term value creation.
• Employees: This filing specifically pertains to executive compensation and does not directly impact the broader employee base, though it reflects standard compensation practices at the executive level.

Next Steps

• Monitoring the vesting of the 37,626 restricted ordinary shares according to their respective lapse dates through June 5, 2028.
• Monitoring the vesting of the 63,328 employee stock options, which become exercisable in tranches from June 3, 2026, to June 4, 2029.

Key Dates

Keywords

STERIS plc, STE, Form 4, Insider Transaction, Equity Grant, Stock Options, Restricted Shares, Executive Compensation, Daniel A. Carestio, Beneficial Ownership